Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Cipla is currently trading at Rs 328.60, up by 3.40 points or 1.05% from its previous closing of Rs 325.20 on the BSE.
The scrip opened at Rs 329.90 and has touched a high and low of Rs 330.70 and Rs. 327.30 respectively. So far 61575 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 359.00 on 07-Feb-2012 and a 52 week low of Rs 273.60 on 06-Sep-2011.
Last one week high and low of the scrip stood at Rs 330.70 and Rs 310.00 respectively. The current market cap of the company is Rs 26420.13 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 33.27% and 29.84% respectively.
Recently, Cipla has slashed its prices on three key cancer medicines by taking advantage of the economies of scale it has managed to get on the product. The entity has significantly dropped its prices on generic Sorafenib, used in advanced kidney cancer, from Rs 27,950 to Rs 6,840.
Sorafenib is the drug on which the Patent Office recently issued a compulsory licence allowing Natco to make a generic copy of this drug, on the payment of a royalty to the innovator company, Bayer. Natco had pegged its price at about Rs 8,900, while Bayer’s price on its branded Sorafenib (Nexavar) is Rs 2.8 lakh.
The company has also reduced its prices on lung cancer drug Gestinib by 60%. Retail prices have come down from Rs 10,200 to Rs 4,250. The original drug is made by Astra Zeneca under the name Iressa.
The third drug that Cipla is dropping the prices is on brain tumour drug Temozolamide in three strengths. Schering makes the original drug. On the 20-mg pack of five, Cipla has been brought down the prices from Rs 1,875 to Rs 480; on the 100-mg strength prices are down from Rs 8,900 to Rs 2,400 and on the 250 mg it is down from Rs 20,250 to Rs 5,000
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1464.85 |
| Dr. Reddys Lab | 5955.65 |
| Cipla | 1477.15 |
| Zydus Lifesciences | 1050.35 |
| Lupin | 1603.55 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
